ELDN
Eledon Pharmaceuticals, Inc.
There isn't enough reported data to score ELDN yet.
ELDN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ELDN's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ELDN PE Valuation
ELDN has no meaningful PE right now: it lost money over the past year.
ELDN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect ELDN's losses to grow, with revenue holding steady.
ELDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$3.08 | +$2.51 |
| Q2 2024 | -$3.11 | +$2.86 |
| Q1 2024 | -$2.45 | +$3.77 |
| Q4 2023 | -$2.41 | +$3.75 |
| Q3 2023 | -$5.59 | -$2.92 |
| Q2 2023 | -$5.97 | -$3.37 |
| Q1 2023 | -$6.22 | -$3.77 |
| Q4 2022 | -$6.16 | -$3.83 |
ELDN is still losing money, but far less than before: $0.73 per share over the past year, against $11.32 at its worst in late 2021.
ELDN Quarterly Revenue
ELDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19M | -$4.5M |
| Q2 2026 | -$22.7M | -$5M |
| Q1 2026 | -$22.6M | -$6.6M |
| Q4 2025 | -$14.1M | +$4.9M |
| Q3 2025 | -$14.5M | -$2.7M |
| Q2 2025 | -$17.7M | -$9.9M |
| Q1 2025 | -$16.1M | -$7.3M |
| Q4 2024 | -$19M | -$9.9M |
ELDN has burned cash in almost every quarter: −$78M over the past year, against −$67M the year before.
ELDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1.1M shares |
| 1 year | +49% | +37.6M shares |
| 3 years | +378% | +90.7M shares |
| 5 years | +674% | +99.9M shares |
ELDN has 115M diluted shares, up 49% from a year ago.
ELDN Net Leverage
ELDN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ELDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.1 | Neutral |
| Stochastic | 26.6 | Neutral |
ELDN's weekly RSI is 40 (neutral) and its Stochastic is 27 (neutral).
ELDN PE vs Healthcare Sector
ELDN has no meaningful PE right now: it lost money over the past year.
ELDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.47 | 4% below |
| 20 week MA | $3.05 | 22% below |
| 50 week MA | $2.90 | 18% below |
| 100 week MA | $3.08 | 23% below |
| 200 week MA | $2.66 | 11% below |
ELDN is in a downtrend: it's below all five of its weekly moving averages, and 11% below its 200-week average.
ELDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.2 | $13.8 | +24% |
| 2021 | $13.8 | $4.63 | -66% |
| 2022 | $4.63 | $2.45 | -47% |
| 2023 | $2.45 | $1.80 | -27% |
| 2024 | $1.80 | $4.35 | +142% |
| 2025 | $4.35 | $1.60 | -63% |
| 2026 YTD | $1.60 | $2.37 | +48% |
ELDN's yearly returns have swung widely, from +142% in 2024 to −66% in 2021. It's up 48% so far in 2026.